CN112138138A - A pharmaceutical composition for treating gout and preparation method thereof - Google Patents

Abstract

The invention provides a pharmaceutical composition for treating gout and a preparation method thereof, wherein the pharmaceutical composition comprises the following effective components, by weight, 18-30 parts of euglena beta-1, 3-glucan, 15-35 parts of compound active alkaloid, 3-15 parts of deep sea fish peptide, 2-5 parts of micromolecular potassium hyaluronate, 5-10 parts of D-glucosamine ketone glutarate, 3-5 parts of glutamine, 2-5 parts of L-alanine, 3-6 parts of L-arginine, 2-5 parts of L-methionine, 3-6 parts of L-lysine, 5-9 parts of L-leucine and 0.2-1 part of vitamin C, and can be prepared by a mixing mode, and the pharmaceutical composition can effectively improve and treat metabolic arthritis such as gout and the like, rheumatic arthritis, and the like, Chronic diseases such as rheumatoid arthritis and the like, joint repair, joint pain reduction, muscle synthesis increase and uric acid metabolism acceleration.

Description

A kind of pharmaceutical composition for treating gout and preparation method thereof

technical field

The present invention relates to a medicine for treating gout and a preparation method thereof, in particular to a pharmaceutical composition for treating gout and a preparation method thereof.

Background technique

Gout is a heterogeneous group of chronic metabolic diseases caused by purine metabolism disorders. Its clinical characteristics are hyperuricemia, recurrent gouty acute arthritis, interstitial nephritis and tophi formation; severe cases are associated with joint deformities. or uric acid urolithiasis. The clinical characteristics of gout are: hyperuricemia; recurrent gouty acute arthritis; tophi formation and deposition of tophi diffuse arthritis; joint deformities.

The formation process of ventilation is mainly caused by the excessive accumulation of uric acid. The main reasons for the accumulation of uric acid are: excessive consumption of high purine foods, problems in purine metabolism in the body, too little excretion, and uric acid cannot be excreted normally. According to the mechanism of uric acid production, to prevent gout, it is necessary to reduce the production of uric acid, to reduce the production of uric acid, it is necessary to reduce the purine in the body, to reduce the purine in the body, it is necessary to reduce the oxidative decomposition of nucleic acid, and the intake of purine, while strengthening the elimination of uric acid. At present, there are many drugs for the treatment of gout on the market, including colchicine, sunflower alkaloids, allopurinol, probenecid and other drugs. A series of side effects such as anaphylactic shock, some plant alkaloids can neutralize uric acid, but patients experience increased pain.

SUMMARY OF THE INVENTION

The technical problem to be solved by the present invention is to provide a pharmaceutical composition for treating gout.

Another technical problem to be solved by the present invention is to provide a preparation method of the above-mentioned pharmaceutical composition for treating gout.

The technical scheme adopted in the present invention is:

A pharmaceutical composition for treating gout, the functional components are composed of Euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, in parts by weight Algae β-1,3-glucan 18-30 parts, compound active alkaloids 15-35 parts, deep-sea fish peptides 3-15 parts, small molecule potassium hyaluronate (molecular weight less than 3000) 2-5 parts, D- Glucosamine Ketoglutarate 5-10 parts, Glutamine 3-5 parts, L-Alanine 2-5 parts, L-Arginine 3-6 parts, L-Methionine 2-5 parts, L- 3-6 parts of lysine, 5-9 parts of L-leucine, 0.2-1 part of vitamin C.

Preferably, the above-mentioned pharmaceutical composition for treating gout contains 26.5 parts by weight of Euglena β-1,3-glucan, 29.4 parts of complex active alkaloids, 7.2 parts of deep-sea fish peptides, and small molecular hyaluronic acid. Potassium acid 3.5 parts, D-glucosamine ketoglutarate 8.6 parts, glutamine 4.1 parts, L-alanine 3.0 parts, L-arginine 4.2 parts, L-methionine 3.5 parts, L-lysine 3.5 parts, L-leucine 6.0 parts, vitamin C 0.5 parts.

The above-mentioned pharmaceutical composition for treating gout can be made into powder, capsule or granule.

The above-mentioned preparation method of the pharmaceutical composition for the treatment of gout, the concrete steps are as follows:

(1) Weigh Euglena β-1,3-glucan, compound active alkaloid, deep-sea fish peptide, small molecule potassium hyaluronate (molecular weight less than 3000), D-glucosamine ketoglutarate by weight parts Salt, Glutamine, L-Alanine, L-Arginine, L-Methionine, L-Lysine, L-Leucine and Vitamin C;

(2) Mix the components in step (1) evenly to obtain.

The beneficial effects of the present invention are:

The pharmaceutical composition for treating gout can effectively improve and treat chronic diseases such as metabolic arthritis such as gout, rheumatoid arthritis, rheumatoid arthritis, etc., repair joints, reduce joint pain, increase muscle synthesis, and accelerate uric acid. metabolism.

Detailed ways

In order to further illustrate the present invention, it is specified in conjunction with the following examples:

Example 1

A pharmaceutical composition for treating gout, the functional components are composed of Euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, among which, Euglena β-1 ,3-glucan 26.5%, compound active alkaloid 29.4%, deep-sea fish peptide 7.2%, small molecule potassium hyaluronate 3.5%, D-glucosamine ketoglutarate 8.6%, glutamine 4.1%, L -Alanine 3.0%, L-Arginine 4.2%, L-Methionine 3.5%, L-Lysine 3.5%, L-Leucine 6.0%, Vitamin C 0.5%.

The above-mentioned pharmaceutical composition for the treatment of gout is made into powder (5g/bag), and the specific steps of the preparation method are as follows:

(1) Weigh Euglena β-1,3-glucan, compound active alkaloid, deep-sea fish peptide, small molecule potassium hyaluronate (molecular weight less than 3000), D-glucosamine ketoglutarate by weight parts Salt, Glutamine, L-Alanine, L-Arginine, L-Methionine, L-Lysine, L-Leucine and Vitamin C;

(2) Mix the components in step (1) evenly to obtain.

Example 2

A pharmaceutical composition for treating gout, the functional components are composed of Euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, among which, Euglena β-1 ,30% 3-glucan, 15% compound active alkaloid, 15% deep-sea fish peptide, 5% small molecule potassium hyaluronate (molecular weight less than 3000), 5% D-glucosamine ketoglutarate, glutamate Amide 5%, L-Alanine 5%, L-Arginine 3%, L-Methionine 2%, L-Lysine 3%, L-Leucine 9%, Vitamin C 1%.

For the preparation method, refer to Example 1.

Example 3

A pharmaceutical composition for treating gout, the functional components are composed of Euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, among which, Euglena β-1 ,3-glucan 18%, compound active alkaloid 35%, deep-sea fish peptide 3%, small molecule potassium hyaluronate (molecular weight less than 3000) 2%, D-glucosamine ketoglutarate 10%, glutamate Amide 3%, L-Alanine 2%, L-Arginine 6%, L-Methionine 5%, L-Lysine 6%, L-Leucine 5%, Vitamin C 0.2%.

For the preparation method, refer to Example 1.

Example 4

A pharmaceutical composition for treating gout, the functional components are composed of Euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, among which, Euglena β-1 ,3-glucan 23%, compound active alkaloid 27%, deep-sea fish peptide 10%, small molecule potassium hyaluronate (molecular weight less than 3000) 4%, D-glucosamine ketoglutarate 8%, glutamate Amide 4%, L-Alanine 3%, L-Arginine 5%, L-Methionine 4%, L-Lysine 4%, L-Leucine 7%, Vitamin C 0.6%.

For the preparation method, refer to Example 1.

Group analysis:

(1) Treat the symptoms and cure the root cause. Paraglucan can reduce uric acid, lower cholesterol, and enhance resistance. The complex active alkaloids directly neutralize uric acid. Glutamine, alanine, arginine (blood vessels), and VC have synergistic effects. The function of protecting the liver and nourishing the kidney; Treating ventilation from the root of nourishing the liver and nourishing the kidney;

(2) Small molecule nano-materials, fast absorption, no toxic side effects, no hormones, no dependence;

(3) Lysine and alanine have a synergistic diuretic effect, which is beneficial to the excretion of uric acid, and cooperates with methionine to inhibit severe hypertension (general ventilation is accompanied by hypertension);

(4) Small molecule potassium hyaluronate and D-glucosamine ketoglutarate can synergistically protect joints, soften joints, soften blood vessels, reduce joint pain and repair joints;

(5) Vitamin C, anti-inflammatory and analgesic, repair the kidneys, reduce the urea content in the body, and promote the absorption of the other four components.

Each component acts synergistically and has a remarkable effect on the treatment of gout.

Experimental example 1

The pharmaceutical composition (5g/bag) described in Application Example 1 is used, and the method of administration is 4 times a day, once every 6 hours, and drinking 500-700ML of purified water each time. After 30 days of taking, it is a course of treatment. There were 50 gout patients in the trial, including 30 young and middle-aged patients. The young patients were 20-45 years old with an average age of 35.5 years old, and the middle-aged and elderly patients were 46-76 years old with an average age of 57.2 years old. All patients were male, and all patients met the diagnostic criteria for gout. The average uric acid level in young patients was 523±71.2 μmol/L, and the average uric acid level in middle-aged and elderly patients was 565±62.3 μmol/L. The average number of clinical attacks was 3.5±0.6 times/year in young patients and 3.8±0.4 times/year in middle-aged and elderly patients.

50 patients with gout were treated in this group. The main lesions were monoarthritis in 23 cases and polyarthritis in 34 cases. The main involved joints were the first toe joint in 46 cases, ankle joint in 16 cases, other toe-metatarsal joints in 11 cases, and knee joints in 11 cases. 9 cases. After the drug treatment of Example 1, 42 cases were completely relieved, 7 cases were improved, and the clinical effective rate was 98.0%.

Experimental example 2

Select a group of 8 patients, the age of the patients is 43-61 years old, all of them are male, and the follow-up test is carried out. The uric acid values measured in the venous blood of the 8 patients are all greater than 550umol/L. / bag), 4 times / day, take once every 6 hours, drink 500-700ML pure water each time. Through observation, the uric acid content decreased rapidly on the 5th day, and 6 patients returned to normal values on the 30th day, and all returned to normal after 60 days of treatment.

The above-mentioned embodiments are only to describe the preferred embodiments of the present invention, and do not limit the scope of the present invention. Variations and improvements should fall within the protection scope determined by the claims of the present invention.

Claims (4)

1. A pharmaceutical composition for treating gout, comprising: the functional components comprise beta-1, 3-glucan of euglena, compound active alkaloid, deep sea fish peptide, micromolecule potassium hyaluronate with the molecular weight less than 3000, D-glucosamine ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, wherein the euglena beta-1, 3-glucan is 18-30 parts, the compound active alkaloid is 15-35 parts, the deep sea fish peptide is 3-15 parts, the micromolecule potassium hyaluronate is 2-5 parts, the D-glucosamine ketoglutarate is 5-10 parts, the glutamine is 3-5 parts, the L-alanine is 2-5 parts, the L-arginine is 3-6 parts, the L-methionine is 2-5 parts, 3-6 parts of L-lysine, 5-9 parts of L-leucine and 0.2-1 part of vitamin C.

2. The pharmaceutical composition for the treatment of gout according to claim 1, wherein: 26.5 parts of euglena beta-1, 3-glucan, 29.4 parts of compound active alkaloid, 7.2 parts of deep sea fish peptide, 3.5 parts of micromolecular potassium hyaluronate, 8.6 parts of D-glucosamine ketoglutarate, 4.1 parts of glutamine, 3.0 parts of L-alanine, 4.2 parts of L-arginine, 3.5 parts of L-methionine, 3.5 parts of L-lysine, 6.0 parts of L-leucine and 0.5 part of vitamin C.

3. The pharmaceutical composition for the treatment of gout according to claim 1, wherein: the medicine composition is powder, capsule or granule.

4. The process for preparing a pharmaceutical composition for treating gout according to claim 1, wherein: the method comprises the following specific steps:

(1) weighing euglena beta-1, 3-glucan, composite active alkaloid, deep sea fish peptide, micromolecular potassium hyaluronate (the molecular weight is less than 3000), D-aminoglucosone glutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C according to the parts by weight;

(2) and (2) uniformly mixing the components in the step (1).